Format

Send to

Choose Destination
World J Gastroenterol. 2017 Jul 28;23(28):5115-5126. doi: 10.3748/wjg.v23.i28.5115.

Myo-inositol reduces β-catenin activation in colitis.

Author information

1
Emily M Bradford, Corey A Thompson, Tatiana Goretsky, Terrence A Barrett, Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, United States.

Abstract

AIM:

To assess dietary myo-inositol in reducing stem cell activation in colitis, and validate pβ-cateninS552 as a biomarker of recurrent dysplasia.

METHODS:

We examined the effects of dietary myo-inositol treatment on inflammation, pβ-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran sodium sulfate-treated colitic mice. Additionally, we assessed nuclear pβ-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia.

RESULTS:

In mice, pβ-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, pβ-cateninS552 staining discriminated ulcerative colitis patients with a history of LGD from those with benign disease.

CONCLUSION:

Enumerating crypts with increased numbers of pβ-cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

KEYWORDS:

Biomarker; Chemoprevention; Colitis-associated cancer; Dysplasia; Stem cell

PMID:
28811707
PMCID:
PMC5537179
DOI:
10.3748/wjg.v23.i28.5115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center